LSL Web-Exclusive Content

  1. How To Spot Fake CRA Candidates — Before Scheduling An Interview

    An overview of current trends and a few pointers that will considerably improve your ability to identify candidate fraudulence early in the recruitment process.

  2. Should U.S. Drug Makers Enter Europe Via The Netherlands (Not The UK) Post-Brexit?

    By March 30, 2019, the European Medicines Agency (EMA) will officially relocate its headquarters from London to Amsterdam — just one of many implications of the UK’s departure from the EU. As a result, U.S. pharmaceutical companies could begin turning to the Netherlands instead of the UK when launching new medicines in Europe post Brexit.

  3. FDA’s Gottlieb Addresses Effort to Advance New Innovations

    In a nearly 3,700 word missive by Scott Gottlieb, posted on August 29, 2018, the FDA commissioner attempts to bring some clarity to efforts by the agency to bring more innovation into the drug development process. Gottlieb notes innovative new technology platforms, such as digital health, targeted medicines, and regenerative medicine, including cell and gene therapies products, are helping the industry advance drug development.

  4. The Appeal Of A Good Underdog Story

    Like many people, I’ve always loved a good underdog story, and recently Life Science Leader has had some good ones. We also have a great CEO Corner coming up in our September issue that talks about what it’s like going from being a VC to founding and running a biopharma.

  5. What Can Biosimilar Developers Learn From The 1990s Biopharma Industry?

    This article highlights some of the early biologics industry decisions and thought processes and the subsequent actions and opportunities biosimilars create for the pharma industry.

  6. Three Challenges Facing The Life Sciences Sector

    The life sciences sector is a British success story. Government figures show that it generated more than £20 billion in turnover in 2015 and provided 90,000 jobs in 2016. It’s also a sector that is used to challenges. Let’s take a look at three of the top challenges facing this industry.

  7. Brexit: The Good, The Bad, And The Chaos

    With just over half a year to go until the divorce date, and roughly two months until European Chief Brexit Negotiator Michel Barnier’s self-imposed October deadline for a Brexit deal, it has started to feel like we are finally seeing some concrete progress when it comes to Brexit.

  8. Surveying The U.S. Regulatory Landscape For Cell And Gene Therapies

    The FDA has been issuing guidance documents addressing gene therapy development issues for approximately 20 years — a remarkable dedication of resources to an area that did not have a licensed product until 2017. Of the six gene therapy-related draft guidances the agency issued last month, two represent the first of the “suite of disease-specific guidance documents on the development of specific gene therapy products” Commissioner Scott Gottlieb promised in Dec. 2017. 

  9. Idealism Vs. Reality: Potential Issues Impacting President’s Plan To Lower Drug Prices

    In looking at the President’s plan for lowering drug prices, a significant chasm exists between idealism and reality. While it will be important to take all factors into consideration, some key potential issues merit close attention.

  10. President Trump, Communist China, and Pharma Outsourcing

    President Clinton once said to reject permanent normal trade relations with China would be a mistake of hugely historic proportions. But years later will history judge “free" trade with China "a blunder of truly historic proportions from which America will never recover”? Enter Donald Trump. Our drug industry, dependent on China, should join the public discourse.